Get the Stockscreener App
0.571
11.36%
-0.0732
After Hours:
.56
-0.011
-1.93%
Transcode Therapeutics Inc Stock (RNAZ) Forecast
The Transcode Therapeutics Inc (RNAZ) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $3.90, representing a +583.01% increase from the current price of $0.571. The highest analyst price target is $4.9583, and the lowest is $2.8417.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month RNAZ Price Target
Average 10.36
(+1,715% Upside)
Is Transcode Therapeutics Inc (RNAZ) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 65.57 | Neutral |
| STOCH(9,6) | 72.47 | Neutral |
| STOCHRSI(14) | 70.22 | Neutral |
| MACD(12,26) | 0.0675 | Buy |
| ADX(14) | 36.22 | Buy |
| William %R | -32.14 | Neutral |
| CCI(14) | 107.38 | Buy |
Buy: 3
Sell: 0
Neutral: 4
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
0.4572
Buy
|
0.4859
Buy
|
| MA20 |
0.3562
Buy
|
0.4114
Buy
|
| MA50 |
0.3164
Buy
|
0.4411
Buy
|
| MA100 |
0.7184
Sell
|
1.3672
Sell
|
| MA200 |
1.3107
Sell
|
11.29
Sell
|
Buy: 6
Sell: 4
Neutral: 0
Summary: Buy
According to our latest analysis, RNAZ could be considered a Strong Buy, with 17 technical analysis indicators signaling 9 Buy signals, 4 signaling Sell signals and 4 Neutral signals. This might be a good time to open fresh positions on RNAZ, as trading bullish markets is always a lot easier
- RSI (Relative Strength Index): The RSI(14) value of 65.57 indicates that RNAZ is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 72.47 indicates that RNAZ is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 70.22 indicates that RNAZ is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- ADX (Average Directional Index): The ADX value of The ADX value of 36.22 suggests a moderate trend in the market. It indicates that there is more conviction behind the directional movement compared to lower ADX values. You should consider this as a potential opportunity to enter trades in the direction of the trend.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of 107.38 indicates that RNAZ is overbought. This means that the price has moved significantly higher than its average, indicating a potential selling opportunity.
Long-term RNAZ price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Transcode Therapeutics Inc financial reports and earnings history, Transcode Therapeutics Inc (RNAZ) stock could reach $23.32 by 2030, $279.62 by 2040 and $381.74 by 2050. See the projected annual prices until 2050 of the Transcode Therapeutics Inc stock below:
- Transcode Therapeutics Inc (RNAZ) is expected to reach an average price of $111.96 in 2035, with a high prediction of $114.24 and a low estimate of $114.16. This indicates an $19,507% rise from the last recorded price of $0.571.
- Transcode Therapeutics Inc (RNAZ) stock is projected to chart a bullish course in 2040, with an average price target of $283.22, representing an $49,501% surge from its current level. The forecast ranges from a conservative $4.2363 to a sky-high $279.62.
- Our analysts predict Transcode Therapeutics Inc (RNAZ) to jump 27,667% by 2045, soaring from $158.73 to an average price of $158.55, potentially reaching $161.33. While $158.73 is the low estimate, the potential upside is significant.
- Transcode Therapeutics Inc (RNAZ) stock is expected to climb by 2050, reaching an average of $376.99, a $65,923% jump from its current level. However, a wide range of estimates exists, with high and low targets of $381.74 and $377.49, respectively, highlighting the market's uncertainty.
Transcode Therapeutics Inc Stock (RNAZ) Year by Year Forecast
Transcode Therapeutics Inc Stock (RNAZ) Price Forecast for 2024
Our forecast for RNAZ stock price in 2024 now indicates an average price target of $25.60 with a high forecast of $51.20 and a low forecast of $0.00422. The average prediction reflects an increase of +4,384% from the last recorded price of $0.571.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| November, 2024 | $1.5583 | $2.8417 | $4.9583 | +172.91% |
| December, 2024 | $2.8723 | $3.8683 | $5.243 | +403.02% |
Transcode Therapeutics Inc Stock (RNAZ) Price Forecast for 2025
Transcode Therapeutics Inc Stock (RNAZ) is expected to reach an average price of $10.88 in 2025, with a high prediction of $20.74 and a low estimate of $1.0216. This indicates an +1,805% rise from the last recorded price of $0.571.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2025 | $13.84 | $2.2452 | $16.44 | +2,324% |
| February, 2025 | $11.41 | $8.853 | $18.52 | +1,898% |
| March, 2025 | $0.8216 | $1.0216 | $16.29 | +43.88% |
| April, 2025 | $15.31 | $3.5368 | $2.3479 | +2,581% |
| May, 2025 | $10.14 | $13.48 | $13.08 | +1,676% |
| June, 2025 | $7.8709 | $11.17 | $9.7979 | +1,278% |
| July, 2025 | $11.06 | $10.73 | $9.6591 | +1,837% |
| August, 2025 | $11.49 | $13.69 | $9.8447 | +1,912% |
| September, 2025 | $16.86 | $11.46 | $8.7069 | +2,853% |
| October, 2025 | $20.63 | $18.75 | $19.71 | +3,513% |
| November, 2025 | $20.44 | $20.64 | $20.74 | +3,479% |
| December, 2025 | $13.66 | $16.41 | $19.30 | +2,292% |
Transcode Therapeutics Inc Stock (RNAZ) Price Forecast for 2026
The predicted value for Transcode Therapeutics Inc (RNAZ) in 2026 is set at an average of $12.93. Estimates vary from a peak of $16.54 to a trough of $9.3138, indicating an +2,164% surge from the present price of $0.571.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $16.26 | $12.37 | $13.56 | +2,747% |
| February, 2026 | $15.39 | $15.64 | $15.15 | +2,595% |
| March, 2026 | $16.45 | $16.44 | $16.54 | +2,781% |
| April, 2026 | $15.10 | $15.49 | $14.71 | +2,545% |
| May, 2026 | $15.94 | $15.25 | $15.10 | +2,691% |
| June, 2026 | $16.20 | $16.05 | $16.31 | +2,737% |
| July, 2026 | $14.74 | $14.78 | $15.74 | +2,481% |
| August, 2026 | $14.05 | $14.13 | $14.31 | +2,360% |
| September, 2026 | $13.31 | $13.23 | $13.56 | +2,230% |
| October, 2026 | $12.17 | $12.21 | $12.77 | +2,032% |
| November, 2026 | $10.88 | $10.89 | $11.73 | +1,806% |
| December, 2026 | $9.3053 | $9.3138 | $10.41 | +1,530% |
Transcode Therapeutics Inc Stock (RNAZ) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Transcode Therapeutics Inc (RNAZ) is $27.32, with a high forecast of $54.26 and a low forecast of $0.3753. This indicates an +4,684% increase from the last price of $0.571.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $7.99 | $7.9948 | $8.9419 | +1,299% |
| February, 2027 | $6.0255 | $6.0654 | $7.6475 | +955.25% |
| March, 2027 | $4.3861 | $4.4288 | $5.563 | +668.14% |
| April, 2027 | $3.0131 | $3.1301 | $3.9872 | +427.70% |
| May, 2027 | $1.7134 | $1.7347 | $2.6428 | +200.07% |
| June, 2027 | $56.14 | $0.3753 | $52.54 | +9,732% |
| July, 2027 | $56.81 | $53.29 | $54.26 | +9,849% |
| August, 2027 | $48.06 | $52.46 | $52.43 | +8,317% |
| September, 2027 | $47.84 | $50.18 | $47.38 | +8,278% |
| October, 2027 | $48.10 | $47.07 | $45.60 | +8,324% |
| November, 2027 | $47.56 | $48.42 | $44.85 | +8,229% |
| December, 2027 | $55.14 | $48.91 | $47.53 | +9,556% |
Transcode Therapeutics Inc Stock (RNAZ) Price Forecast for 2028
In 2028, Transcode Therapeutics Inc (RNAZ) is projected to reach an average price of $40.89, with a high projection of $51.37 and a low estimate of $30.41. This indicates an +7,061% rise from the last price of $0.571.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $51.50 | $49.68 | $49.05 | +8,919% |
| February, 2028 | $45.46 | $49.22 | $45.94 | +7,861% |
| March, 2028 | $30.24 | $31.64 | $41.98 | +5,195% |
| April, 2028 | $29.50 | $30.53 | $27.10 | +5,066% |
| May, 2028 | $43.87 | $30.41 | $42.67 | +7,584% |
| June, 2028 | $52.33 | $44.79 | $50.32 | +9,065% |
| July, 2028 | $48.80 | $49.20 | $51.37 | +8,446% |
| August, 2028 | $46.37 | $46.96 | $43.83 | +8,021% |
| September, 2028 | $46.43 | $46.52 | $45.09 | +8,032% |
| October, 2028 | $41.89 | $45.29 | $43.35 | +7,237% |
| November, 2028 | $51.27 | $43.93 | $49.19 | +8,879% |
| December, 2028 | $52.13 | $51.47 | $50.53 | +9,030% |
Transcode Therapeutics Inc Stock (RNAZ) Price Forecast for 2029
The 2029 price forecast for Transcode Therapeutics Inc Stock (RNAZ) is $37.31 on average, with a high prediction of $50.46 and a low estimate of $24.16. This represents an +6,434% increase from the previous price of $0.571.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $43.25 | $49.51 | $50.46 | +7,474% |
| February, 2029 | $38.67 | $42.27 | $42.54 | +6,672% |
| March, 2029 | $40.73 | $39.01 | $39.52 | +7,034% |
| April, 2029 | $40.51 | $40.23 | $40.43 | +6,995% |
| May, 2029 | $37.18 | $38.42 | $40.10 | +6,411% |
| June, 2029 | $36.29 | $36.53 | $36.21 | +6,255% |
| July, 2029 | $35.64 | $35.84 | $35.45 | +6,142% |
| August, 2029 | $33.89 | $33.94 | $35.42 | +5,835% |
| September, 2029 | $31.23 | $31.29 | $32.56 | +5,369% |
| October, 2029 | $28.55 | $28.55 | $30.48 | +4,901% |
| November, 2029 | $26.60 | $26.77 | $27.76 | +4,559% |
| December, 2029 | $24.15 | $24.16 | $25.38 | +4,130% |
Transcode Therapeutics Inc Stock (RNAZ) Price Forecast for 2030
Transcode Therapeutics Inc Stock (RNAZ) is expected to reach an average price of $56.01 in 2030, with a high forecast of $110.68 and a low forecast of $1.3405. This signifies an +9,709% surge from the last price of $0.571.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $20.84 | $20.85 | $23.32 | +3,550% |
| February, 2030 | $18.16 | $18.16 | $20.15 | +3,080% |
| March, 2030 | $15.48 | $15.48 | $17.46 | +2,611% |
| April, 2030 | $12.20 | $12.20 | $14.76 | +2,036% |
| May, 2030 | $8.7579 | $8.7822 | $11.45 | +1,434% |
| June, 2030 | $6.0573 | $6.1136 | $8.0377 | +960.82% |
| July, 2030 | $2.75 | $2.8799 | $5.3498 | +381.62% |
| August, 2030 | $114.88 | $1.3405 | $110.68 | +20,020% |
| September, 2030 | $109.18 | $109.03 | $107.18 | +19,020% |
| October, 2030 | $105.64 | $103.87 | $107.15 | +18,401% |
| November, 2030 | $90.33 | $101.13 | $97.96 | +15,720% |
| December, 2030 | $96.82 | $98.70 | $96.55 | +16,857% |
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):